Evaluation of cell viability and nitric oxide release after treatment of Hepatocellular Carcinoma cells (HepG2) with Ruta graveolens
Main Article Content
Abstract
Hepatocellular carcinoma (HCC) is a type of neoplasm of high-frequency occurrence and late diagnosis. Therefore, medicine must act in a multidisciplinary and preventive manner to give patients a better prognosis. Homeopathy appears as a possible therapeutic tool to treat these patients, emphasizing significant results regarding quality of life and longevity. This article aimed to evaluate the effect of homeopathic dilutions of Ruta graveolens in the D35 potency on the in vitro cell viability and nitric oxide quantification of hepatocellular carcinoma cells (HepG2). The results showed a critical cytotoxic activity and high production of nitric oxide of the cells when the medicine to the culture. These results indicate that Ruta D35 has action potential in inhibiting HepG2 tumor cell growth, being an important and promising therapeutic tool for treating patients diagnosed with hepatocellular carcinoma if these results be confirmed in vivo.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Tümen D, Heumann P, Gülow K, Demirci C-N, Cosma L-S, Müller M, Kandulski A. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines. 2022; 10(12):3202. https://doi.org/10.3390/biomedicines10123202
3. Garg T, Shrigiriwar A, Habibollahi P, et al. Intraarterial Therapies for the Management of Hepatocellular Carcinoma. Cancers (Basel). 2022;14(14):3351. Published 2022 Jul 10. doi:10.3390/cancers14143351
4. Sas Z, Cendrowicz E, Weinhäuser I, Rygiel TP. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. Int J Mol Sci. 2022;23(7):3778. Published 2022 Mar 29. doi:10.3390/ijms23073778
5. Träger-Maury S, Tournigand C, Maindrault-Goebel F, Afchain P, de Gramont A, Garcia-Larnicol M.-L, Gervais H, & Louvet C. [Use of complementary medicine by cancer patients in a French oncology department]. Bulletin Du Cancer, 2007;94(11), 1017–1025.
6. Kumar A, Sharma M, Prajapati S, & Gupta P. Adjuvant Approach to Mitigate the Adverse Effects of Cancer Treatments Using Homeopathic Medicines. Current Cancer Therapy Reviews, 2022;18(4), 252–261. doi:10.2174/1573394718666220512163517
7. Fuselier C, Dufay E, Berquand A, et al. Dynamized ultra-low dilution of Ruta graveolens disrupts plasma membrane organization and decreases migration of melanoma cancer cell. Cell Adh Migr. 2023;17(1):1-13. doi:10.1080/19336918.2022.2154732
8. Parray S A, Bhat J U, Ahmad G, Jahan N, Sofi G, & IFS M. Ruta graveolens: from traditional system of medicine to modern pharmacology: an overview. Am J Pharm Tech Res, 2012; 2(2), 239-52.
9. Baker D H A, Ibrahim E A, Kandeil A, & Baz F K. Sterols Bioactivity Of Ruta graveolens L. and Murraya paniculata L. International Journal of Pharmacy and Pharmaceutical Sciences, 2017; 9(2), 103.
doi: 10.22159/ijpps.2017v9i2.15790
10. Huang JT, Zhang S, Yang YH, et al. Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. Clin Med Insights Oncol. 2022;16:11795549221134832. Published 2022 Nov 11. doi:10.1177/11795549221134832
11. Träger-Maury S, Tournigand C, Maindrault-Goebel F, et al. Use of complementary medicine by cancer patients in a French oncology department. Bull Cancer (Paris). 2007;94:1017–1025.
12. Priti Kumar, Arvindhan Nagarajan, Pradeep D Uchil. Analysis of Cell Viability by the MTT Assay. Cold Spring Harb Protoc. 2018 Jun 1;2018(6). doi10.1101/pdb.prot095505.
13. Lundberg JO, Weitzberg E. Nitric oxide signaling in health and disease. Cell. 2022;185(16):2853-2878. doi:10.1016/j.cell.2022.06.010
14. Khan FH, Dervan E, Bhattacharyya DD, McAuliffe JD, Miranda KM, Glynn SA. The Role of Nitric Oxide in Cancer: Master Regulator or Not? Int. J. Mol. Sci. 2020, 21, 9393; doi:10.3390/ijms21249393
15. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et al. (2013). Low-dose irra- diation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589–602.
16. Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AR, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, et al. (2016). T cell cancer ther- apy requires CD40-CD40L activation of tumor necrosis factor and inducible ni- tric-oxide-synthase-producing dendritic cells. Cancer Cell 30, 377–390.
17. Soundararajan L, Dharmarajan A, Samji P. Regulation of pleiotropic physiological roles of nitric oxide signaling. Cell Signal. 2023;101:110496. doi:10.1016/j.cellsig.2022.110496
18. Vannini F, Kashfi K, Nath N. The dual role of iNOS in cancer. Redox Biol. 2015, 6, 334–343.
19. Girotti AW, Fahey J, Korytowski W. Role of nitric oxide in hyper-aggressiveness of tumor cells that survive various anti-cancer therapies. Critical Reviews in Oncology/Hematology, Volume 179, 2022. https://doi.org/10.1016/j.critrevonc.2022.103805